Fate Therapeutics Files 8-K: Board & Compensation Updates
Ticker: FATE · Form: 8-K · Filed: Jan 6, 2025 · CIK: 1434316
| Field | Detail |
|---|---|
| Company | Fate Therapeutics Inc (FATE) |
| Form Type | 8-K |
| Filed Date | Jan 6, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $56,250 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing
TL;DR
Fate Therapeutics filed an 8-K on 12/31/24 covering board changes and executive pay.
AI Summary
On December 31, 2024, Fate Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also includes financial statements and exhibits, indicating ongoing corporate governance and financial reporting activities for the period ending December 31, 2024.
Why It Matters
This filing provides insight into the company's leadership structure and how executive compensation is being managed, which can influence investor confidence and strategic direction.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain any immediate negative financial or operational news.
Key Players & Entities
- Fate Therapeutics, Inc. (company) — Registrant
- December 31, 2024 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors or executive officers?
The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' but does not specify the names or details within the provided text.
What are the key details regarding the compensatory arrangements of certain officers?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of information, but the specific details of these arrangements are not included in the provided text.
What is the fiscal year end for Fate Therapeutics, Inc.?
The fiscal year end for Fate Therapeutics, Inc. is December 31.
What is the SEC file number for Fate Therapeutics, Inc.?
The SEC file number for Fate Therapeutics, Inc. is 001-36076.
What is the business address of Fate Therapeutics, Inc.?
The business address of Fate Therapeutics, Inc. is 12278 Scripps Summit Dr., San Diego, CA 92131.
Filing Stats: 1,250 words · 5 min read · ~4 pages · Grade level 12.5 · Accepted 2025-01-06 16:01:28
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share FATE The Nasdaq
- $56,250 — lchko will receive cash compensation of $56,250 a month (the "Compensation") upon compl
Filing Documents
- d900848d8k.htm (8-K) — 31KB
- d900848dex101.htm (EX-10.1) — 52KB
- 0001193125-25-002153.txt ( ) — 214KB
- fate-20241231.xsd (EX-101.SCH) — 3KB
- fate-20241231_lab.xml (EX-101.LAB) — 17KB
- fate-20241231_pre.xml (EX-101.PRE) — 11KB
- d900848d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Strategic Advisory Services Agreement between the Registrant and J. Scott Wolchko, dated as of December 31, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 6, 2025 Fate Therapeutics, Inc. By: /s/ Cindy R. Tahl Cindy R. Tahl Chief Legal and Compliance Officer